Company intelligence / Profile preview

New Amsterdam Genomics

Manhattan, New York, USAnagenomics.com ↗

Ownership: Private
Development stage: Commercial

Overview

New Amsterdam Genomics offers an advanced AI-powered genomics platform that integrates whole exome/genome sequencing with clinical data to provide actionable health insights. Their reports have led to life-changing findings in 45% of clients. The technology continuously updates as new research emerges. Clinical examples include identifying causative mutations in rare diseases and providing guidance for cancer management.

Therapeutic areas: Oncology
Modalities: DNA sequencingWhole Exome Sequencing (WES)Whole Genome Sequencing (WGS)
Industry: Molecular Diagnostics

Partnerships

General partnerships with doctors, hospitals, EHR providers, pharmaceutical companies, health insurance companies—no specific names disclosed

Beyond the preview

Go deeper on New Amsterdam Genomics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on New Amsterdam Genomics.

Explore the full profile